Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial - Roden, M; Weng, J; Eilbracht, J; Delafont, B; Kim, G; Woerle, H J; Broedl, U C (Lancet Diabetes Endocrinol, 2013)